NCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT06835972 2026-04-09
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04923542 2026-02-06
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT04616183 2025-12-23
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05608252 2025-10-29
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05774899 2025-06-17
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06594679 2025-03-28
NICHOL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT05464173 2024-01-22
CINDERELLA
Fudan University
Phase 1/2 Unknown
NCT03655444 2020-12-03
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Washington University School of Medicine
Phase 1/2 Terminated